The current novel therapeutic regimens for Clostridium difficile infection (CDI) and the potentials of Traditional Chinese Medicine in treatment of CDI

Crit Rev Microbiol. 2019 Sep-Nov;45(5-6):729-742. doi: 10.1080/1040841X.2019.1700905. Epub 2019 Dec 14.

Abstract

Clostridium difficile infection (CDI) is featured as the dysbiosis of gut microbiota and consequent mild diarrhoea or severe pseudomembranous colitis. However, the frequent recurrence of CDI following treatment course challenged the antibiotic therapy. Currently, to address the relapse of CDI, several novel therapeutic approaches have emerged, including Bezlotoxumab, SYN-004 (Ribaxamase), RBX2660, and faecal microbial transplant. Traditional Chinese Medicine (TCM) is an old medical system accumulated for thousands of years. Orientated by syndrome-based treatment, TCM functions in a multicomponent and multitarget mode. This old medical system showed superiority over conventional medical treatment, particularly in the treatment of complex disorders, including CDI. In the present review, we will elaborate the TCM intervention in the management of CDI and others disorders via restoring the gut microbiota dysbiosis. We hope that this review will deepen our understanding of TCM as an alternative to CDI treatment. However, more rigorously designed basic researches and randomised controlled trials need to conduct to appraise the function mechanisms and effects of TCM. Finally, it is concluded that the combined therapeutic potentials of TCM and western medicine could be harness to resolve the recurrence and improve the outcome of CDI.

Keywords: Clostridium difficile infection; Traditional Chinese Medicine (TCM); clinical therapeutics; gut microbiota.

Publication types

  • Review

MeSH terms

  • Animals
  • Clostridioides difficile / physiology
  • Clostridium Infections / microbiology
  • Clostridium Infections / therapy*
  • Gastrointestinal Microbiome
  • Humans
  • Medicine, Chinese Traditional*